Literature DB >> 27683753

IL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis.

Laura K Johnston1, Chia-Lin Hsu1, Rebecca A Krier-Burris1, Krishan D Chhiba1, Karen B Chien1, Andrew McKenzie2, Sergejs Berdnikovs1, Paul J Bryce3.   

Abstract

Eosinophils are important in the pathogenesis of many diseases, including asthma, eosinophilic esophagitis, and eczema. Whereas IL-5 is crucial for supporting mature eosinophils (EoMs), the signals that support earlier eosinophil lineage events are less defined. The IL-33R, ST2, is expressed on several inflammatory cells, including eosinophils, and is best characterized for its role during the initiation of allergic responses in peripheral tissues. Recently, ST2 expression was described on hematopoietic progenitor subsets, where its function remains controversial. Our findings demonstrate that IL-33 is required for basal eosinophil homeostasis, because both IL-33- and ST2-deficient mice exhibited diminished peripheral blood eosinophil numbers at baseline. Exogenous IL-33 administration increased EoMs in both the bone marrow and the periphery in wild-type and IL-33-deficient, but not ST2-deficient, mice. Systemic IL-5 was also increased under this treatment, and blocking IL-5 with a neutralizing Ab ablated the IL-33-induced EoM expansion. The homeostatic hypereosinophilia seen in IL-5-transgenic mice was significantly lower with ST2 deficiency despite similar elevations in systemic IL-5. Finally, in vitro treatment of bone marrow cells with IL-33, but not IL-5, led to specific early expansion of IL-5Rα-expressing precursor cells. In summary, our findings establish a basal defect in eosinophilopoiesis in IL-33- and ST2-deficient mice and a mechanism whereby IL-33 supports EoMs by driving both systemic IL-5 production and the expansion of IL-5Rα-expressing precursor cells.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27683753      PMCID: PMC5101160          DOI: 10.4049/jimmunol.1600611

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

2.  Expression of IL-5 alters bone metabolism and induces ossification of the spleen in transgenic mice.

Authors:  M P Macias; L A Fitzpatrick; I Brenneise; M P McGarry; J J Lee; N A Lee
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow.

Authors:  Adipong Brickshawana; Virginia Smith Shapiro; Hirohito Kita; Larry R Pease
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

4.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.

Authors:  M Kopf; F Brombacher; P D Hodgkin; A J Ramsay; E A Milbourne; W J Dai; K S Ovington; C A Behm; G Köhler; I G Young; K I Matthaei
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

Review 5.  Interleukin (IL)-33: new therapeutic target for atopic diseases.

Authors:  Takeshi Nabe
Journal:  J Pharmacol Sci       Date:  2014-09-10       Impact factor: 3.337

6.  An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor.

Authors:  Maho Suzukawa; Motoyasu Iikura; Rikiya Koketsu; Hiroyuki Nagase; Chise Tamura; Akiko Komiya; Susumu Nakae; Kouji Matsushima; Ken Ohta; Kazuhiko Yamamoto; Masao Yamaguchi
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

7.  Gene microarray analysis reveals interleukin-5-dependent transcriptional targets in mouse bone marrow.

Authors:  Jonas Byström; Thomas A Wynn; Joseph B Domachowske; Helene F Rosenberg
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

8.  Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies.

Authors:  Hongnga Le; Wonyoung Kim; Juyang Kim; Hong R Cho; Byungsuk Kwon
Journal:  Front Immunol       Date:  2013-05-06       Impact factor: 7.561

9.  Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures.

Authors:  C J Sanderson; D J Warren; M Strath
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Type 2 innate lymphoid cells control eosinophil homeostasis.

Authors:  Jesse C Nussbaum; Steven J Van Dyken; Jakob von Moltke; Laurence E Cheng; Alexander Mohapatra; Ari B Molofsky; Emily E Thornton; Matthew F Krummel; Ajay Chawla; Hong-Erh Liang; Richard M Locksley
Journal:  Nature       Date:  2013-09-15       Impact factor: 49.962

View more
  51 in total

1.  Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.

Authors:  Sandhya R Panch; Michael E Bozik; Thomas Brown; Michelle Makiya; Calman Prussin; Donald G Archibald; Gregory T Hebrank; Mary Sullivan; Xiaoping Sun; Lauren Wetzler; JeanAnne Ware; Michael P Fay; Cynthia E Dunbar; Steven I Dworetzky; Paneez Khoury; Irina Maric; Amy D Klion
Journal:  Blood       Date:  2018-05-08       Impact factor: 22.113

2.  Proteomic and Phosphoproteomic Changes Induced by Prolonged Activation of Human Eosinophils with IL-3.

Authors:  Stephane Esnault; Alexander S Hebert; Nizar N Jarjour; Joshua J Coon; Deane F Mosher
Journal:  J Proteome Res       Date:  2018-05-04       Impact factor: 4.466

Review 3.  Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease.

Authors:  Hiam Abdala-Valencia; Mackenzie E Coden; Sergio E Chiarella; Elizabeth A Jacobsen; Bruce S Bochner; James J Lee; Sergejs Berdnikovs
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

4.  Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Authors:  Eva Knuplez; Rebecca Krier-Burris; Yun Cao; Gunther Marsche; Jeremy O'Sullivan; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-03-05       Impact factor: 4.962

Review 5.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

Review 6.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

7.  Influenza A virus directly modulates mouse eosinophil responses.

Authors:  Kim S LeMessurier; Robert Rooney; Hazem E Ghoneim; Baoming Liu; Kui Li; Heather S Smallwood; Amali E Samarasinghe
Journal:  J Leukoc Biol       Date:  2020-05-09       Impact factor: 4.962

8.  Neonatal hyperoxia promotes asthma-like features through IL-33-dependent ILC2 responses.

Authors:  In Su Cheon; Young Min Son; Li Jiang; Nicholas P Goplen; Mark H Kaplan; Andrew H Limper; Hirohito Kita; Sophie Paczesny; Y S Prakash; Robert Tepper; Shawn K Ahlfeld; Jie Sun
Journal:  J Allergy Clin Immunol       Date:  2017-12-15       Impact factor: 10.793

Review 9.  The eosinophil: For better or worse, in sickness and in health.

Authors:  Bruce S Bochner
Journal:  Ann Allergy Asthma Immunol       Date:  2018-02-27       Impact factor: 6.347

10.  Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia.

Authors:  Kristina Johansson; Carina Malmhäll; Patricia Ramos-Ramírez; Madeleine Rådinger
Journal:  Immunology       Date:  2017-10-19       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.